Novartis wins another biosimilar round with an OK for its Rituxan copycat
Novartis just racked up its fourth new biosimilar approval in Europe, this time gaining a thumbs up for its knockoff of Roche megablockbuster Rituxan.
The EC gave the pharma giant’s generics unit Sandoz a green light to sell Rixathon as a cheaper alternative to its branded rival at Roche. And it marks Roche’s second biosimilar competitor, following Celltrion’s win for Truxima, flagged through earlier this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.